Preferred Label : Lanraplenib Succinate;
NCIt definition : The succinate salt form of lanraplenib, an orally available inhibitor of spleen tyrosine
kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon
oral administration, lanraplenib binds to and inhibits the activity of Syk. This inhibits
B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation,
and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a
non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic
tissues and is often overexpressed in hematopoietic malignancies; it plays a key role
in B-cell receptor signaling.;
UNII : QJ2PS903VZ;
InChIKey : SUXNLHAGYIRFJQ-UHFFFAOYSA-N;
CAS number : 1800047-00-0;
NCI Metathesaurus CUI : CL1412147;
Origin ID : C174889;
UMLS CUI : C5421002;
Semantic type(s)
- concept_is_in_subset
